Detailed Narrative
Strategic Evolution and Financial Outperformance
Ligand Pharmaceuticals achieved a defining year in 2025, with full-year adjusted EPS exceeding original guidance by over 30% and royalty revenue growing 48%. This performance reflects strategic changes initiated in 2023, including a lean operating structure, focused investment strategy, and the strength of its royalty portfolio. The company's core revenue grew 43% year-over-year to $240 million, demonstrating strong operating leverage and higher royalty contributions.
Accelerated Business Development and Portfolio Management
The company is accelerating its business development efforts in 2026, expanding its team and deepening its pipeline, supported by a strong capital base of over $1 billion in deployable capital. A systematic portfolio management strategy was launched in 2025 to drive value in development-stage partnerships, focusing on proactive communication, identifying new investment opportunities, and broadening existing collaborations. This approach aims to ensure partners have necessary support, including additional investments for high-conviction programs.
QTORIN Rapamycin: Positive Phase 3 Data and Significant Market Opportunity
Palvella Therapeutics announced highly statistically significant positive top-line data for its Phase 3 SELVA trial of QTORIN rapamycin for microcystic lymphatic malformations (mLM). The drug demonstrated a +2.13 point improvement on the IGA scale, with 95% of participants showing improvement. QTORIN rapamycin has Breakthrough Therapy, Orphan Drug, and Fast Track designations. Palvella plans to submit an NDA in H2 2026, targeting over 30,000 diagnosed mLM patients in the U.S. The drug also showed positive Phase 2 results for cutaneous venous malformations (cVM), with a potential market of over 50,000 U.S. patients. Palvella projects peak annual sales of $1 billion to $3 billion across both indications, translating to $100 million to $300 million in peak annual royalty revenue for Ligand.
Lasofoxifene Re-partnering and Pipeline Progress
Ligand successfully re-partnered lasofoxifene, a selective estrogen receptor modulator (SERM), with LeonaBio (formerly Athira Pharma) after its previous developer, Sermonix Pharmaceuticals, faced financial challenges. LeonaBio completed a $90 million PIPE to support the Phase 3 ELAINE 3 trial for ER-positive/HER2-negative metastatic breast cancer, which is over 50% enrolled with top-line data expected in mid-2027. Lasofoxifene demonstrated a 13-month median PFS in Phase 2 studies. Ligand holds a tiered 6% to 10% royalty on worldwide net sales, with management estimating peak sales of approximately $1 billion, potentially yielding $80 million in annual royalties to Ligand.
Key Commercial Product Performance
FILSPARI continues strong commercial performance in IgAN, with Q4 US net sales of $103 million (up 108% YoY) and FY25 US net sales of $322 million. Global FILSPARI sales (royalty basis) reached $355 million in 2025. Merck's Ohtuvayre, a strong launch in COPD history, generated approximately $500 million in sales in its first full calendar year, with Q4 sales growing over 40% sequentially. CAPVAXIVE is rapidly approaching blockbuster status with FY25 net sales of $755 million. Recordati's Qarziba reported FY25 net sales of EUR 159 million, growing 12%.
Broader Late-Stage Pipeline and Market Dynamics
Ligand's late-stage pipeline is active, including Qarziba (U.S. approval, Ewing sarcoma), BOT/BAL (Phase 3), Orchestra's AVIM therapy and Virtue-SAB trials (Phase 3), Castle Creek's D-Fi (Phase 3), and Tzield (expedited review for Stage 3 T1D, age eligibility lowering). The company notes the growing demand for royalty financing, with the market doubling in the last five years, becoming a strategic capital structure tool for biopharmaceutical companies regardless of broader market conditions.